Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 1;5(11):e2242140.
doi: 10.1001/jamanetworkopen.2022.42140.

Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease

Nicolas Hoertel  1   2   3 , David R Boulware  4 , Marina Sánchez-Rico  3 , Anita Burgun  5 , Frédéric Limosin  1   2   3
Affiliations

Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease

Nicolas Hoertel et al. JAMA Netw Open. .
No abstract available

Plain language summary

This cohort study examines the prevalence of contraindications to nirmatrelvir-ritonavir in patients hospitalized with COVID-19.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

References

    1. US Food and Drug Administration . Fact sheet for healthcare providers: emergency use authorization for Paxlovid. December 2021. Accessed March 3, 2022. https://www.fda.gov/media/155050/download
    1. Williamson EJ, Walker AJ, Bhaskaran K, et al. . Factors associated with COVID-19–related death using OpenSAFELY. Nature. 2020;584(7821):430-436. doi:10.1038/s41586-020-2521-4 - DOI - PMC - PubMed
    1. Lim S, Tignanelli CJ, Hoertel N, Boulware DR, Usher MG. Prevalence of medical contraindications to nirmatrelvir/ritonavir in a cohort of hospitalized and nonhospitalized patients with COVID-19. Open Forum Infect Dis. 2022;9(8):ofac389. doi:10.1093/ofid/ofac389 - DOI - PMC - PubMed
    1. Hoertel N, Sánchez-Rico M, Gulbins E, et al. ; AP-HP / Université de Paris / INSERM COVID-19 research collaboration, AP-HP COVID CDR Initiative, “Entrepôt de Données de Santé” AP-HP Consortium . Association between FIASMAs and reduced risk of intubation or death in individuals hospitalized for severe COVID-19: an observational multicenter study. Clin Pharmacol Ther. 2021;110(6):1498-1511. doi:10.1002/cpt.2317 - DOI - PMC - PubMed
    1. Hoertel N, Sánchez-Rico M, Gulbins E, et al. ; AP-HP/Université de Paris/INSERM COVID-19 research collaboration/AP-HP COVID CDR Initiative/“Entrepôt de Données de Santé” AP-HP Consortium . Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study. Transl Psychiatry. 2022;12(1):90. doi:10.1038/s41398-022-01804-5 - DOI - PMC - PubMed